12:00 AM
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fibrocaps: Phase II data

The single-blind, U.S. Phase II FC-002 US trial in 70 patients undergoing spinal, peripheral vascular or general surgery showed that topical Fibrocaps followed by the Gelfoam absorbable gelatin sponge met the primary endpoint of reducing mean time to hemostasis vs. Gelfoam alone (1.9 vs. 4.8 minutes, p<0.001). Fibrocaps followed by...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >